Compare AYI & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AYI | TECH |
|---|---|---|
| Founded | 2001 | 1976 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2B | 9.5B |
| IPO Year | N/A | 1989 |
| Metric | AYI | TECH |
|---|---|---|
| Price | $363.75 | $58.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 14 |
| Target Price | ★ $395.17 | $71.23 |
| AVG Volume (30 Days) | 282.5K | ★ 1.9M |
| Earning Date | 01-08-2026 | 02-04-2026 |
| Dividend Yield | 0.19% | ★ 0.55% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 12.53 | 0.49 |
| Revenue | ★ $4,345,600,000.00 | $1,216,732,000.00 |
| Revenue This Year | $10.92 | $2.33 |
| Revenue Next Year | $5.15 | $7.05 |
| P/E Ratio | ★ $28.96 | $119.71 |
| Revenue Growth | ★ 13.14 | 3.85 |
| 52 Week Low | $216.81 | $46.01 |
| 52 Week High | $379.17 | $79.28 |
| Indicator | AYI | TECH |
|---|---|---|
| Relative Strength Index (RSI) | 51.49 | 42.98 |
| Support Level | $348.94 | $56.84 |
| Resistance Level | $377.15 | $61.20 |
| Average True Range (ATR) | 9.72 | 2.01 |
| MACD | -1.32 | -0.53 |
| Stochastic Oscillator | 49.00 | 18.93 |
Acuity is a leading industrial technology company that offers lighting, lighting controls, and intelligent building solutions. Acuity, Inc. designs, manufactures, and brings to market products and services relating to these and other offerings. Acuity, Inc. has two reportable segments: Acuity Brands Lighting and Acuity Intelligent Spaces. ABL sells commercial, architectural, and specialty lighting, including components and control systems. AIS offers building management and audio/visual solutions to help make buildings intelligent.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.